Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24

Articles

19310 items
7:59 PM, May 04, 2018  |  BioCentury | Strategy

Thinking globally, acting locally

BeiGene Ltd.’s hire of Pfizer Inc. veteran Xiaobing Wu is one of the loudest signals to date that regulatory and reimbursement reforms have made it attractive to develop and commercialize innovative drugs in China. Wu’s...
6:46 PM, May 04, 2018  |  BioCentury | Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
5:12 PM, May 04, 2018  |  BioCentury | Finance

Splitting Ironwood

Ironwood Pharmaceuticals Inc. has accomplished what many biotechs aspire to but few achieve. It has built a high-growth GI business on the cusp of profitability, and discovered and developed a well-stocked pipeline of clinical candidates...
5:06 PM, May 04, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 11 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) 12-month EPS; Source: Yahoo! Finance, Financial Times, company websites CompanyDatePre/post mkt1Q18 EPS est1Q17 EPSExpected chgMyriad Genetics...
3:26 PM, May 04, 2018  |  BioCentury | Finance

Voucher equilibrium

At $110 million, the sticker price on a Priority Review voucher from Spark Therapeutics Inc. (NASDAQ:ONCE) appears to be the new normal. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) purchased the voucher on April 30; Spark received it in...
10:57 AM, May 04, 2018  |  BioCentury | Politics, Policy & Law

A Remembrance: An exceptional responder

Jane Reese-Coulbourne was an exceptional responder. In 1990, faced with a diagnosis of advanced breast cancer, she enrolled in a clinical trial at the National Cancer Institute, enduring a grueling regimen of high doses of...
9:31 AM, May 04, 2018  |  BioCentury | Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...
5:05 AM, May 03, 2018  |  BioCentury | Finance

Foresite into data

With a new $668 million fund, Foresite Capital is positioning itself to invest in more healthcare companies that use data science and machine learning in drug discovery and development, diagnostics, and patient identification and monitoring....
3:02 AM, May 03, 2018  |  BioCentury | Finance

Rock the Casma

The recent discovery of autophagy-inducing targets led Third Rock Ventures to launch Casma Therapeutics Inc. with a $58.5 million series A to develop therapeutics that promote autophagy and ameliorate cellular distress in inflammatory, neurodegenerative, muscular...
5:46 PM, Apr 27, 2018  |  BioCentury | Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed, former...

Pages